SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM A PHASE 3 TRIAL

被引：0
|
作者：
McInnes, Iain B. [1 ]
Mease, Philip [2 ,3 ]
Ritchlin, Christopher T. [4 ]
Rahman, Proton [5 ]
Gottlieb, Alice B. [6 ]
Kirkham, Bruce [7 ]
机构：
[1] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[2] Swedish Med Ctr, Seattle, WA USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Univ Rochester, Allergy Immunol & Rheumatol Div, Rochester, NY USA
[5] Mem Univ, Fac Med, St John, NF, Canada
[6] New York Med Coll, Dept Dermatol, Valhalla, NY 10595 USA
[7] Guys & St Thomas NHS Fdn Trust, London, England
来源：
RHEUMATOLOGY | 2017年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
072
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [1] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results from a Phase 3 Trial
    McInnes, Kin B.
    Mease, Philip J.
    Ritchlin, Christopher T.
    Rahman, Proton
    Gottlieb, Alice B.
    Kirkham, Bruce
    Kajekar, Radhika
    Delicha, Evie Maria
    Pricop, Luminita
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [2] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM A PHASE 3 TRIAL, FUTURE 2
    McInnes, I. B.
    Mease, P. J.
    Ritchlin, C.
    Rahman, P.
    Gottlieb, A.
    Kirkham, B.
    Kajekar, R.
    Delicha, E. M.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 145 - 145
  • [3] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial
    Mease, Philip J.
    Kavanaugh, Arthur
    Reimold, Andreas
    Tahir, Hasan
    Rech, Juergen
    Hall, Stephen
    Geusens, Piet
    Pascale, Pellet
    Delicha, Evie Maria
    Pricop, Luminita
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
    Hall, S.
    Mease, P.
    Kavanaugh, A.
    Reimold, A.
    Tahir, H.
    Rech, J.
    Geusens, P.
    Pascale, P.
    Delicha, E.
    Pricop, L.
    Mpofu, S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 37 - 38
  • [5] Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial
    Mease, Philip J.
    Kavanaugh, Arthur
    Reimold, Andreas
    Tahir, Hasan
    Rech, Juergen
    Hall, Stephen
    Geusens, Piet
    Pascale, Pellet
    Delicha, Evie Maria
    Pricop, Luminita
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [6] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5 YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
    Mease, Philip J.
    Kavanaugh, Arthur
    Reimold, Andreas
    Tahir, Hasan
    Rech, Juergen
    Hall, Stephen
    Geusens, Piet
    Pellet, Pascale
    Delicha, Eumorphia Maria
    Pricop, Luminita
    Mpofu, Shephard
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 917 - 917
  • [7] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL
    Mease, P. J.
    Kavanaugh, A.
    Reimold, A.
    Tahir, H.
    Rech, J.
    Hall, S.
    Geusens, P.
    Pascale, P.
    Delicha, E. M.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 952 - 953
  • [8] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 FUTURE 2 STUDY
    Nash, P.
    McInnes, I. B.
    Rahman, P.
    Gottlieb, A. B.
    Kirkham, B.
    Ding, K.
    Pricop, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 379 - 379
  • [9] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 4-YEAR RESULTS FROM THE PHASE 3 FUTURE 2 STUDY
    McInnes, Iain B.
    Kirkham, Bruce
    Nash, Peter
    Rahman, Proton
    Gottlieb, Alice B.
    Ding, Kevin
    Pricop, Luminita
    RHEUMATOLOGY, 2019, 58
  • [10] Ixekizumab provides sustained improvement in signs and symptoms in patients with active psoriatic arthritis: Results from a phase 3 trial
    Helliwell, P.
    Lespessailles, E.
    Shuler, C. L.
    Mallbris, L.
    Erickson, J.
    Burkhardt, N.
    Fleischmann, R.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 42 - 44
12345